NCT04291729View on ClinicalTrials.gov

Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

March 19, 2020

Study Completion Date

March 19, 2020

Conditions
COVID-19
Interventions
DRUG

Ganovo+ritonavir+/-Interferon nebulization

Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.

Trial Locations (1)

330000

The Ninth Hospital of Nanchang, Nanchang

Sponsors
All Listed Sponsors
collaborator

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY

lead

The Ninth Hospital of Nanchang

OTHER

NCT04291729 - Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter